For UK researchers, peptide discovery is moving earlier into the digital environment.

Before a sequence is synthesised, many research teams now use machine learning, structure prediction and molecular simulation to decide which candidates deserve wet-lab attention. This does not remove the need for synthesis, analytical chemistry or biological testing. It changes the order of operations.

Instead of testing every plausible sequence, you can use computational tools to narrow a large design space into a smaller, better-documented candidate panel.

That distinction matters. AI can accelerate candidate selection. It cannot certify what is inside a vial, confirm a synthesis outcome or replace experimental evidence.

What in-silico peptide screening actually involves

“In silico” refers to computational analysis performed before, or alongside, laboratory work. In peptide research, this can include:

• Generating new amino acid sequences.
• Predicting peptide structure or conformational preferences.
• Modelling peptide–protein interactions.
• Estimating solubility, stability, aggregation tendency or other physicochemical properties.
• Ranking candidates against defined design criteria.
• Updating predictions using results from wet-lab experiments.

Several types of models may be combined in one workflow. Protein language models learn statistical patterns in biological sequences. Structure-prediction systems estimate three-dimensional conformations. Generative models propose new sequences. Molecular dynamics and docking can then provide additional computational filters.

The goal is not to ask an AI system for “the best peptide” and accept the answer. The goal is to define a transparent scoring and decision process that helps you prioritise candidates.

A typical AI-assisted peptide workflow

A practical design–build–test–learn cycle can be organised into six stages.

1. Define the research question

Start with a specific question and measurable constraints. These may include:

• Target protein or interface.
• Desired sequence length.
• Charge and hydrophobicity limits.
• Solubility requirements.
• Resistance to aggregation.
• Permitted or excluded amino acids.
• Whether the candidate contains terminal modifications or non-natural residues.

The more clearly you define the design problem, the easier it becomes to interpret model output.

2. Generate candidate sequences

Generative models can produce many sequences rapidly. Depending on the research objective, teams may use transformers, variational autoencoders, diffusion models, genetic algorithms or reinforcement learning.

A large candidate library is useful only if it is paired with appropriate controls. Please record the model version, training data source, generation settings and filtering rules. Without that information, you may struggle to reproduce the candidate set later.

3. Predict structure and interaction geometry

Structure prediction can help researchers ask whether a proposed sequence is compatible with a target conformation or binding surface.

AlphaFold and related systems have changed structural biology by making protein-structure prediction more accessible. ProteinMPNN and RFdiffusion have also demonstrated how computational methods can support sequence and structure design. The foundational AlphaFold research published in Nature and subsequent work on RFdiffusion-based protein design provide useful background for understanding this progression.

For peptide researchers, the important point is practical: a predicted structure is a prioritisation aid, not a certificate of biological activity.

Short peptides can be highly flexible. Their conformations may change with solvent, pH, temperature, concentration, terminal chemistry and interaction partners. A single predicted structure can therefore give a false impression of certainty.

4. Apply multi-objective filters

Binding is only one consideration. A candidate may score well against a target while presenting other research liabilities.

Your screening process may therefore include predictions or calculations related to:

• Conformational stability.
• Solubility.
• Aggregation propensity.
• Charge distribution.
• Proteolytic sensitivity.
• Synthetic accessibility.
• Potential off-target interactions.
• Compatibility with the intended assay conditions.

A multi-objective approach is usually more realistic than optimising one score in isolation. A candidate with a strong predicted interaction but poor solubility may be less useful than a slightly lower-scoring sequence that can be produced and tested consistently.

5. Synthesis and analytical verification

After computational prioritisation, select a manageable panel for synthesis. This is where the digital workflow meets physical chemistry.

The synthesised material must be checked for identity and purity before biological or biochemical testing. If the laboratory result does not match the computational input, any later conclusion becomes difficult to interpret.

6. Feed experimental data back into the model

Use wet-lab results to test the model, not simply to confirm it.

Record which candidates were synthesised, which analytical results were obtained, how each assay was performed and whether the observed data agreed with the predictions. These data can support active-learning cycles and improve future prioritisation.

Why structure prediction is changing candidate selection

Historically, peptide selection often relied on literature precedent, sequence intuition, library screening or broad empirical testing. These approaches remain valuable, but they can be expensive and slow when candidate space expands.

Structure prediction adds another layer of information. It allows you to inspect:

• Whether a sequence adopts a plausible fold.
• Which residues appear close to a target surface.
• Whether a binding motif is exposed or buried.
• Whether a sequence produces multiple competing conformations.
• Whether an apparent interaction depends on a fragile geometry.

This can help a UK research group decide which candidates should proceed first.

However, confidence scores require careful interpretation. A high confidence score may indicate that a model has found a stable computational solution. It does not establish affinity, selectivity, stability in the assay matrix or performance in a biological system.

Short, flexible peptides deserve particular caution. Research published in npj Soft Matter demonstrates how machine learning, genetic algorithms, reinforcement learning and molecular simulation can be combined to study peptide aggregation propensity. It also illustrates a wider principle: computational predictions become more useful when they are connected to defined physical measurements and experimental validation.

The UK research context in 2026

The UK is participating in a wider European shift towards computationally assisted discovery. Academic projects, biotechnology companies and collaborative programmes are exploring how AI can support peptide design, delivery systems and biomolecular engineering.

The University of Oxford Nuffield Department of Medicine, for example, has listed research focused on AI-designed peptides for precision delivery. At European level, the PeptimAIze project is developing AI approaches for multi-objective peptide design.

For UK researchers, this development creates both an opportunity and a responsibility. Computational workflows should be documented with the same discipline applied to laboratory protocols.

Please retain:

• Model and software versions.
• Input sequences and preprocessing steps.
• Training and test-set information where available.
• Random seeds and generation parameters.
• Structure-prediction confidence metrics.
• Docking or simulation settings.
• Candidate-selection thresholds.
• Full experimental results, including negative findings.

Do not present a model output as a validated research result. Treat it as a hypothesis that must move through the appropriate experimental stages.

Why HPLC, mass spectrometry and batch records remain non-negotiable

AI can rank a sequence. It cannot verify the material that arrives in your laboratory.

Third-party analytical testing remains central to research integrity. For each research compound, you should expect documentation that connects the material to a specific batch or lot.

HPLC: assessing chromatographic purity

High-performance liquid chromatography separates components in a sample and provides a chromatographic profile. Review the main peak, integration table, retention time and any reported impurities.

A percentage alone is not enough. Please check that the reported purity corresponds to the specific batch and that the underlying chromatogram is available for review.

Mass spectrometry: supporting identity

Mass spectrometry helps compare the observed molecular mass with the expected mass for the compound. It can support identity confirmation and identify obvious discrepancies.

Mass spectrometry should not be treated as a complete substitute for sequence-level characterisation in every research context. Its value is strongest when interpreted alongside HPLC and the compound’s documented chemistry.

COA and batch traceability

A Certificate of Analysis should function as a batch-specific technical record. Check for:

• Compound name and stated quantity.
• Batch or lot number matching the vial.
• Test date.
• Laboratory identity.
• HPLC data and integration table.
• Mass-spectrometry data.
• Reported specifications and results.
• Storage or handling information where relevant.

A generic PDF, an unmatched lot number or a purity claim without supporting data should be treated as a warning sign.

How AXIOM supports protocol-led peptide research

At AXIOM Health, we focus on research-grade compounds selected and formulated with clear scientific intent. Third-party testing, clean formulations and batch documentation are important because they help researchers separate computational assumptions from measured material properties.

If your protocol uses established compounds as controls, comparators or reference materials, you can review our NAD+ research compound, KPV research peptide, AOD9604 research peptide and BPC-157 research peptide.

These products are supplied for research purposes only. Product availability does not constitute evidence for a therapeutic application, and no product should be used in humans or animals outside the appropriate legal, ethical and institutional framework.

A practical checklist for UK researchers

Before moving an AI-prioritised candidate into a wet-lab programme, please ask:

1. What exact question is the model answering?
2. Was the sequence included in, or excluded from, the training data?
3. How was data leakage assessed?
4. Does the candidate remain plausible across more than one modelling method?
5. Were solubility, aggregation and synthetic constraints considered?
6. Are the model assumptions documented?
7. Is the synthesised material linked to a batch-specific COA?
8. Do HPLC and MS results support purity and identity?
9. Can another researcher reproduce the computational ranking?
10. What experimental result would falsify the computational hypothesis?

The strongest workflows do not treat AI and analytical chemistry as competing approaches. They use them in sequence.

Computational screening reduces unnecessary synthesis and helps you prioritise candidates. Wet-lab testing establishes what the material does. HPLC, mass spectrometry and batch-specific documentation establish what the material is.

In 2026, that combination: faster digital prioritisation with disciplined experimental verification: is becoming the practical standard for precise peptide research.

Further reading

• AlphaFold structure prediction research
• RFdiffusion and de novo protein design
• AI-driven peptide design and aggregation modelling
• PeptimAIze European research project
• How to read a peptide COA

All AXIOM Health compounds are supplied for research purposes only. They are not medicines, supplements or products for human consumption.